Drug Discovery
By
Can ProFound Therapeutics and Novartis’ $750M AI-Driven Cardiovascular Pact Redefine Drug Discovery from the Human Proteome?
Key Highlights AI Meets Proteomics: A New Paradigm in Cardiovascular DiscoveryIn a bold step toward AI-enabled medicine, ProFound…
Is Insilico’s AI-Driven UAE University Alliance the Catalyst for a New Generation of Biotech Talent?
Key Highlights Academic Meets AI Innovation in UAEInsilico Medicine, a leader in generative AI for drug discovery, has…
Is Sanofi’s $632M AI Bet on Formation Bio the Next Big Immunology Breakthrough?
French pharma giant doubles down on AI-native R&D with gusacitinib licensing deal targeting new inflammatory indication Key Takeaways…
Accelerating Drug Discovery with Artificial Intelligence: Strategic Insights from Pharma’s Biggest AI Alliances
Executive SummaryThe convergence of artificial intelligence (AI) and drug discovery is a strategic imperative. Pharmaceutical giants including Sanofi,…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate the Discovery of Next-Gen Cancer Drugs Targeting RAS Mutations?
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
At VivaTech 2025, Can NVIDIA, Sanofi, and TetraScience Unlock the Full Potential of Scientific AI Despite a 20-Exabyte Data Barrier?
Key Highlights The 20-Exabyte Problem: Data, Not Models, Is the Limiting FactorAt The Rise of Scientific AI panel…
